KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Leases (2019 - 2025)

Historic Current Leases for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to $45.5 million.

  • Alnylam Pharmaceuticals' Current Leases rose 867.12% to $45.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $45.5 million, marking a year-over-year increase of 867.12%. This contributed to the annual value of $45.5 million for FY2025, which is 867.12% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Current Leases of $45.5 million as of Q4 2025, which was up 867.12% from $44.8 million recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Current Leases high stood at $46.1 million for Q2 2025, and its period low was $38.9 million during Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Current Leases value was $41.7 million (recorded in 2024), while the average stood at $42.2 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Current Leases skyrocketed by 3399.79% in 2021, and later tumbled by 321.22% in 2024.
  • Alnylam Pharmaceuticals' Current Leases (Quarter) stood at $40.5 million in 2021, then rose by 3.5% to $42.0 million in 2022, then dropped by 1.09% to $41.5 million in 2023, then increased by 0.91% to $41.9 million in 2024, then rose by 8.67% to $45.5 million in 2025.
  • Its last three reported values are $45.5 million in Q4 2025, $44.8 million for Q3 2025, and $46.1 million during Q2 2025.